Handbook of Clinical medicine

M0 or T4 N0–2 M0 Reproduced with permission from Edge, SB et al. (Eds.), AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010. Treatment NSCLC: Lobectomy (open or thoracoscopic) is the treatment of choice if medically fi t and aim is curative intent or parenchymal sparing operation for pa- tients with borderline fi tness and smaller tumours ((T1a–b, N0, M0). Radical radio- therapy for patient with stage I, II, III NSCLC. Chemotherapy ± radiotherapy for more advanced disease. Regimens may be platinum based, eg with monoclonal antibodies targeting the epidermal growth factor receptor (cetuximab). SCLC: consider sur- gery with limited stage disease. Chemotherapy ± radiotherapy if well enough. Palli- ation: Radiotherapy is used for bronchial obstruction, SVC obstru ction, haemoptysis, bone pain, and cerebral metastases. SVC stent + radiot herapy and dexamethasone for SVC obstruction. Endo bronchial therapy: tracheal stenting, cryotherapy, laser, brachytherapy (radioactive source is placed close to the tumour). Pleural drainage/ pleurodesis for symptomatic pleural eff usions. Drugs: analgesia; steroids; anti- emetics; cough linctus; bronchodilators; antidepressants. Prognosis Non-small cell: 50% 2yr survival without spread; 10% with spread. Small cell: median survival is 3 months if untreated; 1–1½yrs if treated. Prevention Stop smoking (p93). Prevent occupational exposure to
